Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection

C Trépo; D Ouzan; T Fontanges; M Chevallier; P Chossegros; F Degos; P Chevallier; O Hantz

doi:10.1016/s0168-8278(86)80111-8

Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection

J Hepatol. 1986:3 Suppl 2:S129-35. doi: 10.1016/s0168-8278(86)80111-8.

Authors

C Trépo, D Ouzan, T Fontanges, M Chevallier, P Chossegros, F Degos, P Chevallier, O Hantz

PMID: 2439569
DOI: 10.1016/s0168-8278(86)80111-8

Abstract

Acyclovir only demonstrated activity in CAH patients with low HBV replication (DNA-p less than or equal to 80 cpm). In those, oral acyclovir 4 g/day for 4 months was able to permanently inhibit DNA-p in 5/5 cases without significant side-effects.

MeSH terms

Acyclovir / therapeutic use*
Hepatitis B / complications
Hepatitis B / therapy*
Hepatitis B virus / drug effects
Hepatitis B virus / physiology
Hepatitis D / complications*
Hepatitis, Chronic / therapy*
Humans
Interferons / therapeutic use*
Vidarabine / therapeutic use
Virus Replication / drug effects

Substances

Interferons
Vidarabine
Acyclovir